# The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

> **NCT05789524** · PHASE2 · TERMINATED · sponsor: **ApcinteX Ltd** · enrollment: 60 (actual)

## Conditions studied

- Hemophilia a
- Hemophilia B

## Interventions

- **DRUG:** SerpinPC

## Key facts

- **NCT ID:** NCT05789524
- **Lead sponsor:** ApcinteX Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-07-06
- **Primary completion:** 2024-11-14
- **Final completion:** 2025-02-28
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** Study terminated due to business and strategic decision
- **Last updated:** 2025-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05789524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05789524, "The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05789524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*